$47.90
0.00% day before yesterday
Nasdaq, Oct 17, 10:00 pm CET
ISIN
US87410C1045
Symbol
TRML

Talaris Therapeutics Inc Stock price

$47.90
+0.20 0.42% 1M
+31.89 199.19% 6M
+27.62 136.19% YTD
+18.77 64.44% 1Y
+36.97 338.36% 3Y
-27.61 36.57% 5Y
-27.61 36.57% 10Y
-27.61 36.57% 20Y
Nasdaq, Closing price Fri, Oct 17 2025
+0.00 0.00%
ISIN
US87410C1045
Symbol
TRML
Industry

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$991.4m
Net debt
positive
Cash
$239.2m
Shares outstanding
25.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.8
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | -50.9%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-102.0m | -
EBIT
$-102.0m | $-104.1m
Net Income
$-88.3m | $-92.6m
Free Cash Flow
$-86.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-127.8% | -
EBIT
-130.0% | -16.0%
Net Income
-150.8% | -26.5%
Free Cash Flow
-197.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
Financial Health
Equity Ratio
97.1%
Return on Equity
-24.4%
ROCE
-39.4%
ROIC
-
Debt/Equity
0.0
More
EPS
$-3.4
FCF per Share
$-3.4
Short interest
4.3%
Employees
74
Rev per Employee
$0.0
Show more

Is Talaris Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Talaris Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Talaris Therapeutics Inc forecast:

6x Buy
40%
9x Hold
60%

Analyst Opinions

15 Analysts have issued a Talaris Therapeutics Inc forecast:

Buy
40%
Hold
60%

Financial data from Talaris Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
72% 72%
-
- Research and Development Expense 80 80
90% 90%
-
-102 -102
128% 128%
-
- Depreciation and Amortization 0.04 0.04
110% 110%
-
EBIT (Operating Income) EBIT -102 -102
130% 130%
-
Net Profit -88 -88
151% 151%
-

In millions USD.

Don't miss a Thing! We will send you all news about Talaris Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Talaris Therapeutics Inc Stock News

Neutral
Business Wire
13 days ago
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Tourmaline Bio, Inc. (NasdaqGS: TRML) to Novartis AG. Under the terms of the proposed transaction, shareholders of Tourmaline will receive $48.00 in cash for each share of Tourmaline that they own....
Neutral
GlobeNewsWire
20 days ago
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, i...
Neutral
Business Wire
about one month ago
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Tourmaline Bio, Inc. (NasdaqGS: TRML) to Novartis AG. Under the terms of the proposed transaction, shareholders of Tourmaline will receive $48.00 in cash for each share of Tourmaline that they own....
More Talaris Therapeutics Inc News

Company Profile

Talaris Therapeutics, Inc. engages in cell therapy. It develops methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its technologies are used to treat inherited metabolic enzyme disorders, red blood cell disorders to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company was founded by Suzanne Ildstad in 2002 and is headquartered in Louisville, KY.

Head office United States
CEO Sandeep Kulkarni
Employees 74
Founded 2021
Website www.tourmalinebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today